APPENDIX B 
THE UNIVERSITY 07 TEXAS 
M.D. ANDERSON CANCER CENTER 
Division of Medicine 
Protocol Title: Use of Two Retroviral Markers to Test Relative 
Contribution of Marrow and Peripheral Blood 
Autologous Cells to Recovery After Preparative 
Therapy 
1.0 OBJECTIVES 
2.0 BACKGROUND 
3'.0 BACKGROUND DRUG INFORMATION 
4.0 PATIENT ELIGIBILITY 
5.0 TREATMENT PLAN 
6.0 PRE-TREATMENT EVALUATION 
7.0 EVALUATION DURING STUDY 
8.0 CRITERIA FOR RESPONSE AND TOXICITY 
9.0 CRITERIA FOR REMOVAL FROM STUDY 
10.0 STATISTICAL CONSIDERATIONS 
11.0 REFERENCES 
APPENDIX Al: Zubrod Scale 
APPENDIX A2 : Cardiac Status Scale 
APPENDIX B: Clinical Protocols: Human Gene Transfer 
Proposal 
APPENDIX C: 
APPENDIX D: 
APPENDIX E: 
APPENDIX F: 
APPENDIX G: 
APPENDIX H: 
APPENDIX I: 
CONSENT FORM 
Study Chairman : 
Albert Deisseroth 
study Co-Chairm an 
Hagop Kantarjian, 
Moshe Talpaz, M.D 
Richard champlin, 
Investigational Drug Data Sheet: 
Cyclophosphamide 
Investigational Drug Data Sheet: Etoposide 
Investigational Drug Data Sheet: Interferon 
Gene-Transfer Virus Article 
Preparation of Marking Vector 
Toxicity Criteria 
Evaluation Before and During Therapy 
, M.D. , Ph.D. 
M . D 
M.D. 
[858] 
Recombinant DNA Research, Volume 15 
